Skip to main content

Vertice Launches Thyquidity (levothyroxine sodium) Oral Solution

NEW PROVIDENCE, N.J., Feb. 24, 2021 /PRNewswire/ -- Vertice Pharma ("Vertice"), a specialty pharmaceuticals company focused on improving patients' health, today announced the launch of Thyquidity. Thyquidity is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.*

Thyquidity is a liquid dosage form of levothyroxine administered by a calibrated oral syringe, and is designed to deliver individualized dosing for patients. Thyquidity is a liquid oral solution of levothyroxine sodium containing 100 mcg per 5 mL (20 mcg per mL), and it is supplied in a package of two 100 mL bottles. Thyquidity offers broad dosing flexibility for patients, as well as consistent daily dosing.

"The launch of Thyquidity marks our first branded pharmaceutical prescription product and reflects our ongoing mission to deliver high-quality and affordable pharmaceutical products for patients. Vertice is committed to providing branded and specialty generics products and we look forward to building off the momentum of today's launch," said Scott Meyers, Chief Executive Officer of Vertice Pharma.

Vertice's co-promotion partner is MannKind Corporation (Nasdaq: MNKD). MannKind's sales force will promote Thyquidity to adult and pediatric endocrinologists and other U.S. healthcare providers who treat hypothyroidism.

"Thyquidity fits nicely into our product portfolio of branded and specialty generics and is an exciting launch for the team at Vertice. As we continue to evaluate select opportunities to bring products to market, we are proud to have partnered with MannKind in the launch of this important product," said John Walsh, Head of Specialty Sales and Marketing at Vertice Pharma.

Hypothyroidism, also called underactive thyroid disease, is a common disorder in which the thyroid gland does not produce enough thyroid hormone to meet the needs of the body. The prevalence of hypothyroidism is 4.6% in the US population.1 Symptoms include fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin.2 Most patients require lifelong therapy to treat their hypothyroidism.3

Vertice Pharma was founded in 2015 with a unique focus on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.

Patient Use and Important Safety Information

USE

ThyquidityTM (levothyroxine sodium) oral solution is a prescription, man-made thyroid hormone that is used to treat a condition called hypothyroidism. It is meant to replace a hormone that is usually made by your thyroid gland. Generally, thyroid replacement treatment is to be taken for life. Thyquidity should not be used to treat noncancerous growths or enlargement of the thyroid in patients with normal iodine levels, or in cases of temporary hypothyroidism caused by inflammation of the thyroid gland (thyroiditis).

IMPORTANT SAFETY INFORMATION

This is the most important safety information you should know about Thyquidity. For more information, talk with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see:
http://www.Thyquidity.com/pdf/Prescribing-Information.pdf for full US Prescribing Information including Boxed Warning.

About Vertice Pharma

Vertice Pharma is a specialty pharmaceutical company focused on improving patients' health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey. For more information visit www.verticepharma.com.

References

  1. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. doi: 10.1210/jcem.87.2.8182. PMID: 11836274.
  2. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562. https://pubmed.ncbi.nlm.nih.gov/28336049/
  3. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. https://www.ncbi.nlm.nih.gov/pubmed/25266247.

* Please see http://www.Thyquidity.com/pdf/Prescribing-Information.pdf for full US Prescribing Information including Boxed Warning.

SOURCE Vertice Pharma

Thyquidity (levothyroxine sodium) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.